For investors and partners
Co-invest at the point the risk is already retired.
We open our companies to outside capital once the regulatory pathway and the first contract are in hand — not before.
The proposition
The two risks that kill health technology in this market are the two we take first.
Health technology in the Kingdom fails on regulatory pathway and on procurement. Not on science. A company can have a validated device and a published trial and still never be bought, because the entity was never built to be bought from here.
The studio absorbs both risks before outside capital is invited. By the time a company reaches Series A, the SFDA pathway is open and there is a contracted cluster. What is left for a co-investor to price is execution, which is the risk they are actually equipped to price.
How we are structured
We hold a founder's stake in each company, taken at incorporation, alongside the founding team. First capital comes off our own balance sheet. We are a principal, not an intermediary, and we stay on the cap table.
What we are looking for
Co-investors at Series A into individual companies, and strategic partners — hospital operators, diagnostics groups, and industrial partners — where the relationship starts before the round.
Portfolio pipeline
Eleven companies, by studio stage.
Snapshot as of July 1, 2026
Request access
The portfolio review is available on request.
Company-by-company detail, stage, regulatory status, and the companies currently open to outside capital. Released under NDA to institutional and strategic parties.